Site-directed modification of FVIII

This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.

Saved in:
Bibliographic Details
Main Authors PAN, CLARK Q, MURPHY, JOHN E, STRAUSS, JONATHAN S, TJANDRA, HENDRI, MEI, BAISONG, BARNETT, THOMAS, CHEN, JIANMIN, TANG, LIANG, WAMG, DEQIAN
Format Patent
LanguageEnglish
French
German
Published 07.09.2011
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
Bibliography:Application Number: EP20110153300